We applied AML leukemia cells with NF-κB inhibitor Bay11-7082, and found that Bay11-7082 significantly decreased the protein levels of LPS+ATP induced pNF-κB, pro-caspase-1, pro-IL-1β, cleaved caspase-1 and cleaved IL-1β (Figure 1C, right column 1 and 3, Supplementary Figure 1F). Here, NFKB1 is linked to leukemia.